1.Expression of serum inflammatory cytokines in patients with thyroid tumor and their correlation with thyroid hormones
Jie NIU ; Mingqin GE ; Yilin REN ; Aihua TONG
Chinese Journal of Endocrine Surgery 2022;16(4):452-456
Objective:To explore the expression of serum inflammatory factors in patients with thyroid tumor and their correlation with thyroid hormones.Methods:A total of 92 patients with thyroid tumors (48 cases of thyroid cancer and 44 cases of thyroid adenoma) admitted to Department of Endocrinology in Linyi Central Hospital in Shandong Province from Jan. 2020 to Oct. 2021 were enrolled. 50 healthy volunteers who received physical examination in the hospital during the same period were enrolled in the control group. The serum inflammatory factors [tumor necrosis factor-α (TNF-α) , interleukin-6 (IL-6) , interleukin-17 (IL-17) ] and thyroid hormone expression levels [thyroid stimulating hormone (TSH) , free thyroxin T4 (FT4) , free triiodothyronine (FT3) ] of the three groups were detected. Analysis of variance was used for multi-group comparison, independent sample t test was performed for comparison between groups, Spearman correlation analysis and Logistic regression analysis were made for the risk factors of thyroid cancer. The expression of serum inflammation and thyroid hormones in patients with different stages of thyroid cancer was observed. Results:Serum TNF-α, IL-17, IL-6 from high to low were in the thyroid cancer group (74.61±7.94 ng/L, 68.65±7.05 ng/L, 20.52±2.84 ng/L) , thyroid adenoma group (26.97±3.42 ng/L, 46.31±5.31 ng/L, 13.61±1.58 ng/L) , control group (18.82±2.63 ng/L, 34.52±4.02 ng/L, 8.97±1.06 ng/L) ( F=1596.271, 468.602, 423.351, all P<0.001) ; Serum TSH levels from high to low were in the thyroid cancer group (8.64±1.34 mU/L) , the thyroid adenoma group (5.21±1.02 mU/L) , the control group (3.94±0.85 mU/L) ( F=242.182, P=0.000) . There was no significant difference in serum FT4 or FT3 levels among the three groups ( P=0.753, 0.634) . Correlation analysis indicated that serum TNF-α, IL-17, and IL-6 were positively correlated with the expression level of serum TSH ( r=0.936, 0.726, 759, all P<0.05) . The expression level of TNF- α, IL-17, IL-6 and TSH was significantly higher in patients of stage III and IV than that in patients of stage I and II ( t=2.541, 4.394, 6.390, 4.962, P=0.015, P<0.001, P<0.001, P<0.001) . Multivariate Logistic regression analysis suggested serum TNF-α, IL-17, IL-6 and TSH were all risk factors for thyroid cancer. Conclusions:Serum inflammatory factors and some thyroid hormones (TSH) are generally highly expressed in patients with thyroid tumors, the expression levels of serum inflammatory factors are correlated with the expression of TSH. There are statistically significant differences in the expression levels of serum inflammatory factors and TSH between patients with thyroid cancer of different stages, serum inflammatory factors and TSH are also involved in the occurrence and development of thyroid cancer, and are risk factors for thyroid cancer.
2.The relationship between serum BHMT level and visceral fat area in patients with type 2 diabetes mellitus and its predictive value for diabetic nephropathy
Ping HU ; Yan DAI ; Fuyuan LI ; Mingqin GE
Chinese Journal of Endocrine Surgery 2024;18(4):554-558
Objective:To analyze the relationship between serum betaine homocysteine methyltransferase (BHMT) level and visceral fat area (VAF) in patients with type 2 diabetes mellitus (T2DM) and its predictive value for diabetic nephropathy (DN) .Methods:A retrospective study was conducted to select 170 patients with T2DM admitted to the hospital from Apr. 2021 to Apr. 2023 as the study subjects. According to the occurrence of DN, the patients were divided into two groups: DN group and non-DN group. All patients were tested for serum BHMT and VAF, and the relationship between them was analyzed by bivariate correlation. The baseline data of patients were collected, and the correlation between serum BHMT and VAF levels and DN in patients with T2DM was analyzed by binary Logistic regression. Receiver operating characteristic curve (ROC) was used to analyze the predictive value of serum BHMT and VAF levels for DN in patients with T2DM.Results:DN occurred in 34 of 170 patients with T2DM, with an incidence of 20.00%. The proportion of patients with DN combined with hypertension [61.76% (21/34) ] was higher than that of non-DN group [41.91% (57/136) ]. The levels of glycosylated hemoglobin (HbA1c), homocysteine (Hcy) and VAF were (8.97±1.53) %, (15.87± 5.09) μmol/L, (113.62±18.74) cm 2 respectively, higher than those in non-DN group [ (8.16± 1.27) %, (11.65±4.81) μmol/L, (92.61±14.17) cm 2]. The level of BHMT was (57.74± 9.18) pg/ml, lower than that in non-DN group [ (78.74±11.53) pg/ml] ( P<0.05). The levels of serum creatinine (Scr), blood urea nitrogen (BUN) and urinary albumin excretion rates (UAER) in DN group were (71.74±9.81) μmol/L, (8.18±1.27) mmol/L, (106.61±28.61) mg/24 h respectively, higher than those in non-DN group [ (57.11±10.06) μmol/L, (5.29±1.02) mmol/L, (14.65± 2.52) mg/24 h] ( P<0.05). BHMT was negatively correlated with VAF, Scr, BUN and UAER ( r<0, P<0.05). Binary Logistic regression analysis showed that high levels of HbA1c, Hcy and VAF were risk factors for DN in patients with T2DM ( OR>1, P<0.05). High level of BHMT was a protective factor for DN in patients withT2DM ( OR<1, P<0.05). The results of ROC curve showed that the AUC of BHMT, VAF levels and combined prediction of DN in patients with T2DM were all>0.70, which had certain predictive value, and the combined detection had the highest. Conclusion:Serum BHMT level is negatively correlated with VAF in patients with T2DM, and serum BHMT and VAF levels are closely related to the occurrence of DN in patients with T2DM, both of which can effectively predict the risk of DN in patients.
3.Effects of standardized pain assessment and peer education in cancer pain patients
Tingting HU ; Hongyan REN ; Xiaoxia XU ; Mingqin WANG ; Yana GAO ; Ge ZHANG ; Yuqing CHEN ; Fang ZHOU ; Yu ZHANG ; Li TAO ; Saiqi WANG ; Xiaobing CHEN
Chinese Journal of Modern Nursing 2021;27(6):799-803
Objective:To explore the effect of standardized pain assessment and peer education on self-efficacy, quality of life and pain control of cancer pain patients.Methods:From January 2019 to January 2020, convenience sampling was used to select 162 inpatient cancer patients admitted to Henan Cancer Hospital as the research object. Patients were divided into observation group ( n=82) and control group ( n=80) based on the odd and even numbers of the patient's ward end number. Patients in control group received regular health education and traditional pain assessment. Observation group carried out standardized pain assessment and peer education. We compared self-efficacy, quality of life, pain control of two groups of patients before and after intervention. Results:Before intervention, there was no statistically significant difference between the two groups of patients in terms of dimension scores and total scores of self-efficacy, quality of life ( P>0.05) . After intervention, dimension scores and total scores of self-efficacy and quality of life of cancer pain patients' pain between two groups were higher than those before intervention, and the differences were statistically significant ( P<0.01) . Dimension scores and total scores of self-efficacy and quality of life of cancer pain patients in observation group were higher than those in control group with statistical differences ( P<0.01) . The overall pain control effect of cancer pain patients in observation group was better than that in control group, and the difference was statistically significant ( Z=-3.721, P<0.01) . Conclusions:Standardized pain assessment and peer education applied to the pain management of cancer pain patients can effectively improve the pain control effect and self-efficacy as well as the quality of life.